E3 LRTI Flashcards
definition of CAP
pneumonia that developed outside of the hospital or within the first 48 hours of hospital admission
3 things listed under pathogenesis for CAP, and then which one is most common
Aspiration **
Aerosolization
Bloodborne
which microorganism class is the most common pathogenic organism for CAP?
A. Fungus
B. Bacteria
C. Virus
D. Protozoa
C
most common bacterial pathogen
streptococcus pneumoniae
risk factors for drug resistance : strep pneumo
- age <6 or >65
- prior antibiotic therapy
- comorbid conditions
- recent hospitalization
“more common” atypical bacteria for CAP
mycoplasma pneumoniae
common way mycoplasma pneumo is spread
person to person contact
how is legionella pneumo spread
aerosolization
what is an important thing to consider in an infection caused by staph aereus
get MRSA nasal PCR test to predict value for MRSA in CAP*
5 conditions that serve as risk factors for many pathogens
- alcoholism
- COPD/smoker
- post influenza pneumo
- structural lung disease
- recent antibiotic exposure
clinical presentation of CAP (5)
- sudden onset of fever
- chills
- pleuritic chest pain
- dyspnea
- productive cough
clinical presentation of CAP:
gradual onset with lower severity for ________ and _______ pneumoniae
mycoplasma
chlamydia
clinical presentation of CAP, elderly patients:
classic symptoms may be _________ such as what 2 things
absent
afebrile, mild leukocytosis
4 vitals for clinical presentation of CAP
- febrile
- tachycardia
- hypotensive
- tachypnea
what is rec for all pts with suspicion for CAP
chest x ray
what does sputum look like:
viral:
bacterial:
viral -> clear
bacterial -> gross
when doing a microscopic exam of sputum we only evaluate samples with >__ PMNs and < 10 epithelial cells
25, 10
i dont remember what he said on slide 21 so i will go back and find that later i promise
thanks cole
what are the 2 major criteria for severe CAP? how many of these do you need to qualify it as severe
- septic shock requiring vasopressors
- respiratory failure requiring mechanical ventilation
(only need one of these to occur for severe)
9 minor criteria for severe cap and how many do you need to consider it severe (i dont think we will need to know all of this but might as well throw it in here) i will star ones that came up in his cases tho frfr
- resp rate >30BPM *
- PaO2/FlO2 <250
- multilobar infiltrates
- confusion/disorientation *
- uremia (BUN >20) *
- Leukopenia (WBC <4000)
- Thrombocytopenia (Pit <100,000)
- Hypothermia (temp <36)
- hypotension requiring fluids *
NEED 3 OF THESE
Other tools for CAP:
procalcitonin
when is it clinically useful?
guiding DURATION of treatment
T or F:
procalcitonin is a useful tool to determine antibiotic needs for CAP
false *
what are the two clinical prediction tools for CAP and which one is common
- pneumonia severity index (PSI)
- CURB-65 *
what does CURB-65 do?
estimates mortality for CAP
CAP Empiric therapy, outpatient, NO comorbidities (3)
- amox 1 gm PO Q8h
- doxy 100 mg PO BID
- macrolide resistance <25%: azithromycin
CAP Empiric therapy, outpatient, WITH comorbidities:
monotherapy -> ___
combo therapy -> __
mono: levo, moxi (respiratory FQs)
combo: B-lactam + macrolide OR doxy
what are the comorbidities we focus on for treatment options? (a lot)
- heart disease
- lung disease
- renal disease
- T2DM
- alcoholism
- cancer
- asplenia/immunosuppression (wont be asked about probably)
3 recommended b-lactams for the combos used with outpatient CAP
- amox/clav
- cefpodoxime
- cefuroxime
CAP empiric therapy, non-severe, inpatient, NO comorbidities
mono:
combo:
mono: levo, moxi
combo: B-lactam + macrolide
rec beta lactams for use in inpatient setting for combo therapy
amp/sulbactam (unasyn)
ceftriaxone
CAP empiric therapy, inpatient, severe
combo 1:
combo 2:
combo 1: levo/moxi + b-lactam
combo 2: b-lactam + macrolide
CAP empiric therapy, inpatient:
MRSA risk factors present, what 2 drugs
- vanc
- linezolid
CAP empiric therapy, inpatient:
pseudomonas risk factors present, what 3 drugs
- Piper/Tazo (Zosyn)
- cefepime
- meropenem
3 risk factors for MRSA
- 2-14 days post influenza
- previous MRSA infection
- previous hospitalization and use of IV antibiotics in last 90 days
2 risk factors for Pseudomonas
- previous pseudomonas infection
- previous hospitalization and use of IV antibiotics within last 90 days
T or F:
corticosteroids are a staple in treatment of non-severe CAP
false
if corticosteroids arent recommended in CAP, when is the ONLY time they’d be considered
surviving sepsis guidelines when patient has CAP and septic shock *
recommended duration of CAP therapy
minimum of 5 total days
CAP clinical stability:
- Temp < __
- HR < ____
- RR < ___
- SBP > __
- 38
- 100
- 24
- 90
aspiration pneumonia:
No _______ coverage recommended unless lung abscess or empyema present
anaerobic
HAP= pneumo occuring > __ hours after hospitalization
48
VAP= pneumo occuring > __ hours after endotracheal intubation
48
some of the risk factors for HAP/VAP
- old
- comorbid diseases
- duration of hospitalization
- endotracheal tube
- nasogastric tube
- altered mental status *
- surgery
- previous antibiotic therapy
what is the gold standard for diagnosing HAP/VAP
none idiot
typical presentation of HAP/VAP
new lung infiltrate + clinical signs and sxs ( new onset fevre, purulent sputum, leukocytosis, decline in oxygenation)
Common pathogens for HAP/VAP:
3 aerobic GN bacilli
pseudomonas
enteric GN bacilli (e. coli, kleb, citrobacter)
acinetobacter
Common pathogens for HAP/VAP:
other one
staph aureus
(MRSA greater concern in this population)
T or F:
invasive respiratory cultures have diagnostic threshold
true whatever that means
Respiratory culture diagnostic threshold:
- may hold ________ based on threshold
- protected specimen brush < __ CFU/mL
- BAL: < __ CFU/mL
- antibiotic
- 10^3
- 10^4
what does MDR mean
multi drug resistant
1 risk factor for MDR HAP
prior IV antibiotic use within 90 days
1 risk factor for MRSA HAP/VAP
prior IV antibiotic use within 90 days
2 risk factors for MDR pseudomonas aeruginosa
- prior IV antibiotic use within 90 days
- carbapenems, broad-spectrum b- lactams, FQs
5 risk factors for MDR VAP
- prior antibiotic use within 90 days
- septic shock at time of diagnosis
- acute respiratory distress syndrome prior to diagnosis
- acute renal replacement therapy prior to VAP onset
- > 5 days of hospitalization prior to diagnosis
Empiric therapy - antibiotic choice:
MRSA coverage , 3 risk factors
- typical risk factors for MRSA
- ICUs where > 10-20% MRSA isolates
- treatment where prevalence is unknown
Empiric therapy - antibiotic choice:
MRSA coverage first line choices
- vanc
- linezolid
Empiric therapy - antibiotic choice:
Pseudomonas coverage 2 risk factors
- ICUs where >10% of isolates resistant
- treatment where resistance rates are unknown
Empiric therapy - antibiotic choice:
Pseudomonas coverage 5 drug choices
- Piper/tazo
- cefepime
- imipenem
- meropenem
- levofloxacin
Empiric therapy - HAP (NOT at high risk for mortality) :
goal
provide coverage for MSSA + pseudomonas
Empiric therapy - HAP (NOT at high risk for mortality):
5 drug choices
- Piper/tazo
- cefepime
- imipenem
- meropenem
- levofloxacin
Empiric therapy - HAP (NOT at high risk for mortality, BUT MRSA risk):
drugs
same as last time with the 5 but also consider vanc or linezolid
Empiric therapy - HAP ( HIGH risk for mortality and MRSA risk) (on ventilator support or septic shock):
goal
provide coverage for MRSA + MDR pseudomonas
Empiric therapy - HAP ( HIGH risk for mortality and MRSA risk) (on ventilator support or septic shock):
drugs
PICK 2 DIFF CLASSES: **
- piper/tazo
- cefepime
- imipenem
- meropenem
- levofloxacin
- tobra/amikacin
+ vanc or linezolid
Empiric therapy - VAP:
goal
provide coverage for MRSA + pseudomonas
Empiric therapy - VAP:
when do you choose 2 anti-pseudomonals
risk factors for resistance
Empiric therapy - VAP:
drugs
same as all the other shit with the vanc and linezolid too
Non-beta lactam considerations:
when should daptomycin be used for LRTIs
never dumbass
Non-beta lactam considerations:
Polymyxins (3)
- avoid empiric use if possible
- reserve for pts with high prevalence of MDR pathogens
- Significant nephrotoxicity
Non-beta lactam considerations:
AMGs (3)
- recommend AGAINST use as monotherapy
- avoid empiric use unless necessary
- poor lung penetration, nephrotoxicity, ototoxicity, reports of lower clinical response rates
Non-beta lactam considerations:
tigecycline (2)
- great for polymicrobial infections BUT..
- associated with increased mortality (rip)
Pathogen-Specific therapy:
MSSA (2)
cefazolin, nafcillin
Pathogen-Specific therapy:
Enterobacterales (1 class)
3rd gen cephs
Pathogen-Specific therapy:
ESBL-producer (2)
carbapenem
ceftazidime/avibactam
Pathogen-Specific therapy:
KPC-Producer (3)
- meropenem/vaborbactam
- imipenem/relebactam
- ceftazidime/avibactam
Pathogen-Specific therapy:
NDM/VIM-producer (2)
- ceftazidime/avibactam + aztreonam
- cefederocol
Pathogen-Specific therapy:
Acinetobacter spp (3)
- carbapenem
- amp/sulb
- cefiderocol
duration of therapy for HAP/VAP
7 day if clinically stable
does piperacillin/tazobactam cover ESBL producers
no, usually go to a carbapenem